Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
about
Glucarpidase to combat toxic levels of methotrexate in patientsPopulation pharmacokinetics and pharmacodynamics of oral etoposidePopulation pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.Life-threatening complications following multidose methotrexate for medical management of ectopic pregnancySerum Creatinine Versus Plasma Methotrexate Levels to Predict Toxicities in Children Receiving High-dose Methotrexate.Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients.Plasma levels of 5-fluorouracil after oral and intravenous administration in cancer patientsHigh dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients.Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment.Review of the bioanalytical methods for the determination of methotrexate and its metabolites in in vitro, preclinical and clinical studies: Case studies and perspectives.Folate during antifolate chemotherapy: what we know... and do not know.Integration of modeling and simulation into hospital-based decision support systems guiding pediatric pharmacotherapy.Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trialPerformance characteristics between TDx®FLx and TBA™-25FR for the therapeutic drug monitoring of methotrexate.Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcomaBetween-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery.Mechanisms of antifolate resistance and methotrexate efficacy in leukemia cells.Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy.Preventing and Managing Toxicities of High-Dose MethotrexateGlucarpidase following high-dose methotrexate: update on development.Pharmacokinetics and metabolism of methotrexate: an example for the use of clinical pharmacology in pediatric oncology.Rational administration schedule for high-dose methotrexate in patients with primary central nervous system lymphoma.Evaluation of toxicity after acute accidental methotrexate ingestions in children under 6 years old: a 16-year multi-center review.Clinical management of cytotoxic drug overdose.In vitro activities of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte CFUs.Methotrexate disposition in humans: case studies in ovarian cancer and following high-dose infusion.Critical factors for the reversal of methotrexate cytotoxicity by folinic acid.Early tumor drug pharmacokinetics is influenced by tumor perfusion but not plasma drug exposure.Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.Lack of correlation between methotrexate concentrations in serum, saliva and sweat after 24 h methotrexate infusions.Factors that influence the penetration of methotrexate through solid tissue.High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity.A phase II trial of sequential MTx and 5-FU alternated with 4-epidoxorubicin and cisplatin in advanced gastric cancer.Simple and reliable HPLC method for the monitoring of methotrexate in osteosarcoma patients.Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.Computer Assisted Management of the Critically Ill.Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: a prospectively randomized cross-over study.Pharmacokinetics of glucarpidase in subjects with normal and impaired renal function.
P2860
Q24605014-FFA8D34E-C9BD-4E3B-B0AB-583C5C4DD0A9Q28365888-C6331C06-0EEE-4C83-8ED9-C7F85856D43AQ33399245-047F6739-28C7-4438-99C2-C59C7B525B79Q33402976-6016043A-46AC-438A-87DE-4FABA1450D74Q33427484-D2AF8BCD-CEB1-49A9-8D30-BE76707B9B41Q34247793-B8D19CCD-B7C2-456D-815E-BC849B7C822BQ34517614-6E3A6141-FD24-4C68-8214-79BE0FC0F484Q35640471-453C42C5-B846-4466-A3B1-40FF55913DC7Q35827596-AD7FEF77-35BE-49D1-B1BD-24A2EC02A1C6Q35970344-F0793127-3B1B-4548-89E5-8AAF60524659Q36131520-C7C82F8C-83F6-49BF-AD0F-62D956381272Q36278412-EECC5A70-6BFB-40CB-A243-50E406469EC1Q36478646-A5AE0AB6-296A-4C15-99B9-0167F76443ABQ36503647-57959B34-BD29-4224-A24A-FCE0C5B9292CQ36662204-FC1F47FB-84FC-4957-B871-2239F3D0F5FFQ36789432-79856FD6-49A8-40F2-AEB1-B0DBC2829501Q37034349-9267C12F-EEF7-4497-A373-823CD97A1AD5Q37041124-D9F7EC5A-06C3-4D44-941A-22CDD189590CQ37093674-C0D07CA3-6110-405F-88DF-54DC22F18894Q37156268-E76D4DE4-26C9-47B2-9EE0-7CB4FD7396CFQ37496637-8254B76C-02AC-489D-9837-4AA590BC742EQ37635158-7A2152B9-15EB-449F-97A7-641F29BE11B0Q37951561-40ACFD86-57D8-4A3C-895A-1E4068CBD0B4Q38005196-A56641AD-6A21-4F0F-9113-0A0573D6E5BDQ38668482-0A3163DE-D7F2-46A4-803F-581AC0CF6F26Q39536333-721A114A-B149-4270-9609-075047F89659Q39779567-2DF4642A-A98E-4482-8C54-C82C5396257DQ39780182-14281E3C-5063-413D-856D-E8A1FA156C8DQ41696472-CFF7A263-17DA-45CD-98C0-EC63EE4757F5Q41946729-27D73AA1-53B1-4044-93AF-EEE9B64AC843Q42708326-B9A59D68-40E8-4775-8C99-A84405D9B599Q43229034-B38E7858-56ED-4CC1-8501-C4BB96697001Q43517179-88ED035C-1C51-4671-B84C-E48D62BC53DCQ43924069-A8576322-BB40-411A-8FC4-BB366A69C5CFQ44007136-FA45CBBE-699C-4D2C-A72E-96792CF9236EQ44252346-3815893E-B1B4-4030-B57B-7E1623DD6AEFQ45147872-F48C3F31-4ABF-4AAD-9B23-D8B63CAFB27BQ45779941-701CF714-51FE-4B14-81F1-FC8CA2E6DD27Q46459030-A5153016-7981-493D-94A5-E005821C7B77Q46810140-6988F473-EEED-4A5C-B50D-B27EB8761959
P2860
Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
description
1977 nî lūn-bûn
@nan
1977年の論文
@ja
1977年論文
@yue
1977年論文
@zh-hant
1977年論文
@zh-hk
1977年論文
@zh-mo
1977年論文
@zh-tw
1977年论文
@wuu
1977年论文
@zh
1977年论文
@zh-cn
name
Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
@en
type
label
Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
@en
prefLabel
Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
@en
P2093
P1476
Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity.
@en
P2093
Chabner BA
Rosenberg SA
Stoller RG
P304
P356
10.1056/NEJM197709222971203
P407
P577
1977-09-01T00:00:00Z